Literature DB >> 29067603

Prediction of Non-sentinel Node Status in Patients with Melanoma and Positive Sentinel Node Biopsy: An Italian Melanoma Intergroup (IMI) Study.

Carlo Riccardo Rossi1,2, Simone Mocellin3,4, Luca Giovanni Campana1,2, Lorenzo Borgognoni5, Serena Sestini5, Giuseppe Giudice6, Corrado Caracò7, Adriana Cordova8, Nicola Solari9, Dario Piazzalunga10, Paolo Carcoforo11, Pietro Quaglino12, Virginia Caliendo13, Simone Ribero12,13.   

Abstract

BACKGROUND AND
PURPOSE: Approximately 20% of melanoma patients harbor metastases in non-sentinel nodes (NSNs) after a positive sentinel node biopsy (SNB), and recent evidence questions the therapeutic benefit of completion lymph node dissection (CLND). We built a nomogram for prediction of NSN status in melanoma patients with positive SNB.
METHODS: Data on anthropometric and clinicopathological features of patients with cutaneous melanoma who underwent CLND after a positive SNB were collected from nine Italian centers. Multivariate logistic regression was utilized to identify predictors of NSN status in a training set, while model efficiency was validated in a validation set.
RESULTS: Data were available for 1220 patients treated from 2000 through 2016. In the training set (n = 810), the risk of NSN involvement was higher when (1) the primary melanoma is thicker or (2) sited in the trunk/head and neck; (3) fewer nodes are excised and (4) more nodes are involved; and (5) the lymph node metastasis is larger or (6) is deeply located. The model showed high discrimination (area under the receiver operating characteristic curve 0.74, 95% confidence interval [CI] 0.70-0.79) and calibration (Brier score 0.16, 95% CI 0.15-0.17) performance in the validation set (n = 410). The nomogram including these six clinicopathological variables performed significantly better than five other previously published models in terms of both discrimination and calibration.
CONCLUSIONS: Our nomogram could be useful for follow-up personalization in clinical practice, and for patient risk stratification while conducting clinical trials or analyzing their results.

Entities:  

Mesh:

Year:  2017        PMID: 29067603     DOI: 10.1245/s10434-017-6143-5

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  13 in total

Review 1.  Follow-up of primary melanoma patients with high risk of recurrence: recommendations based on evidence and consensus.

Authors:  Begoña Campos-Balea; Ovidio Fernández-Calvo; Roberto García-Figueiras; Carlos Neira; Carmen Peña-Penabad; Carmela Rodríguez-López; Rocío Vílchez-Simo; María Quindós-Varela
Journal:  Clin Transl Oncol       Date:  2022-03-28       Impact factor: 3.340

2.  Evidence and implementation gaps in management of sentinel node-positive melanoma in the United States.

Authors:  Kristy K Broman; Joshua Richman; Smita Bhatia
Journal:  Surgery       Date:  2022-02-01       Impact factor: 4.348

Review 3.  Lymph node metastasis in melanoma: a debate on the significance of nodal metastases, conditional survival analysis and clinical trials.

Authors:  Mark B Faries; Dale Han; Michael Reintgen; Lauren Kerivan; Douglas Reintgen; Corrado Caracò
Journal:  Clin Exp Metastasis       Date:  2018-05-18       Impact factor: 5.150

4.  Surgeon decision-making for management of positive sentinel lymph nodes in the post-Multicenter Selective Lymphadenectomy Trial II era: A survey study.

Authors:  Jane Yuet Ching Hui; Erin Burke; Kristy K Broman; Schelomo Marmor; Eric Jensen; Todd M Tuttle; Jonathan S Zager
Journal:  J Surg Oncol       Date:  2020-12-01       Impact factor: 3.454

5.  Surveillance of Sentinel Node-Positive Melanoma Patients with Reasons for Exclusion from MSLT-II: Multi-Institutional Propensity Score Matched Analysis.

Authors:  Kristy K Broman; Tasha M Hughes; Lesly A Dossett; James Sun; Michael J Carr; Dennis A Kirichenko; Avinash Sharma; Edmund K Bartlett; Amanda Ag Nijhuis; John F Thompson; Tina J Hieken; Lisa Kottschade; Jennifer Downs; David E Gyorki; Emma Stahlie; Alexander van Akkooi; David W Ollila; Jill Frank; Yun Song; Giorgos Karakousis; Marc Moncrieff; Jenny Nobes; John Vetto; Dale Han; Jeffrey Farma; Jeremiah L Deneve; Martin D Fleming; Matthew Perez; Kirsten Baecher; Michael Lowe; Roger Olofsson Bagge; Jan Mattsson; Ann Y Lee; Russell S Berman; Harvey Chai; Hidde M Kroon; Roland M Teras; Juri Teras; Norma E Farrow; Georgia M Beasley; Jane Yc Hui; Lukas Been; Schelto Kruijff; David Boulware; Amod A Sarnaik; Vernon K Sondak; Jonathan S Zager
Journal:  J Am Coll Surg       Date:  2020-12-13       Impact factor: 6.532

Review 6.  New paradigm for stage III melanoma: from surgery to adjuvant treatment.

Authors:  Paolo Antonio Ascierto; Lorenzo Borgognoni; Gerardo Botti; Michele Guida; Paolo Marchetti; Simone Mocellin; Paolo Muto; Giuseppe Palmieri; Roberto Patuzzo; Pietro Quaglino; Ignazio Stanganelli; Corrado Caracò
Journal:  J Transl Med       Date:  2019-08-14       Impact factor: 5.531

Review 7.  The Role and Necessity of Sentinel Lymph Node Biopsy for Invasive Melanoma.

Authors:  Yasuhiro Nakamura
Journal:  Front Med (Lausanne)       Date:  2019-10-22

Review 8.  An evidence-based approach to positive sentinel node disease: should we ever do a completion node dissection?

Authors:  Jennifer S Downs; David E Gyorki
Journal:  Melanoma Manag       Date:  2019-10-18

9.  Management of melanoma patients during COVID-19 pandemic in an Italian skin unit.

Authors:  Angela Filoni; Paolo Del Fiore; Rocco Cappellesso; Luigi Dall'Olmo; Nick Salimian; Romina Spina; Saveria Tropea; Marco Rastrelli; Francesco Russano; Mattia D'Amico; Alessandra Collodetto; Carlo Riccardo Rossi; Alessandra Buja; Antonella Vecchiato; Mauro Alaibac; Simone Mocellin
Journal:  Dermatol Ther       Date:  2021-03-08       Impact factor: 3.858

10.  A Prognostic Model to Assess Long-Term Survival of Patients on Antiretroviral Therapy: A 15-Year Retrospective Cohort Study in Southwestern China.

Authors:  He Jiang; Qiuying Zhu; Yi Feng; Jinghua Huang; Zongxiang Yuan; Xinjuan Zhou; Guanghua Lan; Hao Liang; Yiming Shao
Journal:  Open Forum Infect Dis       Date:  2021-06-12       Impact factor: 3.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.